Department of Radiation Oncology, Royal Adelaide Hospital, Adelaide, South Australia, Australia.
Clin Oncol (R Coll Radiol). 2013 Jun;25(6):356-61. doi: 10.1016/j.clon.2013.02.004. Epub 2013 Mar 13.
To assess tumour control, visual outcomes and toxicity after radiotherapy for all patients with optic nerve sheath meningiomas (ONSM) treated by a single radiation oncologist at a single institution over a 15 year period. To explore potential predictors of outcomes.
All patients underwent ophthalmological and radiological assessments before radiotherapy. These were repeated at regular intervals after treatment. A retrospective analysis of clinical, dosimetric and radiological data was carried out. Patients with useful vision before radiotherapy were divided into two groups - those with maintained or improved vision and those with a deterioration in vision. The groups were compared using the Mann-Whitney U-test with regard to eight potential predictors of outcome.
Seventeen patients with 18 ONSM were treated with fractionated radiotherapy (46.8-55.8 Gy in 26-31 fractions). No evaluable tumours grew after treatment: control rate 100% (95% confidence interval 82-100%). Using the most common definition of visual function described in the literature, vision was maintained or improved in 89% (95% confidence interval 67-97%) of cases. In those with useful vision before treatment (13 evaluable eyes), visual acuity was maintained or improved in eight (62%, 95% confidence interval 36-82%). There was a suggestion that the time from the onset of symptoms to radiotherapy may influence outcome. Those with stable or better visual acuity after radiotherapy had been observed for a shorter time compared with those who had worse visual acuity (median of 18 months versus 62 months). Acute and late toxicity from radiotherapy was manageable.
Radiotherapy is an extremely effective modality in arresting the growth of ONSM. A longer time from symptom onset to the start of radiotherapy may predict for poorer outcomes.
评估 15 年间由同一位放疗医师在同一家机构对所有视神经鞘脑膜瘤(ONSM)患者进行放疗后的肿瘤控制、视力结果和毒性。探讨潜在的预后预测因素。
所有患者在放疗前均进行眼科和影像学评估,治疗后定期重复评估。对临床、剂量学和影像学数据进行回顾性分析。放疗前有有用视力的患者分为两组 - 视力保持或改善的患者和视力恶化的患者。使用 Mann-Whitney U 检验比较两组 8 种潜在预后预测因素。
17 例 18 例 ONSM 患者接受了分割放疗(26-31 次,46.8-55.8 Gy)。治疗后无可评估肿瘤生长:控制率 100%(95%置信区间 82-100%)。根据文献中最常见的视力功能定义,89%(95%置信区间 67-97%)的病例视力保持或改善。在治疗前有有用视力的患者(13 只可评估的眼睛)中,视力保持或改善的有 8 只(62%,95%置信区间 36-82%)。有迹象表明,从症状发作到放疗的时间可能会影响结果。放疗后视力稳定或更好的患者观察时间比视力更差的患者短(中位数为 18 个月与 62 个月)。放疗的急性和迟发性毒性是可以控制的。
放疗是一种非常有效的控制 ONSM 生长的方法。从症状发作到放疗开始的时间延长可能预示着更差的结果。